166 related articles for article (PubMed ID: 27169997)
1. Molecular Pathways: Targeting DNA Repair Pathway Defects Enriched in Metastasis.
Corcoran NM; Clarkson MJ; Stuchbery R; Hovens CM
Clin Cancer Res; 2016 Jul; 22(13):3132-7. PubMed ID: 27169997
[TBL] [Abstract][Full Text] [Related]
2. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
3. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ
J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911
[TBL] [Abstract][Full Text] [Related]
4. PARP inhibition in prostate cancer.
Nientiedt C; Duensing A; Zschäbitz S; Jäger D; Hohenfellner M; Stenzinger A; Duensing S
Genes Chromosomes Cancer; 2021 May; 60(5):344-351. PubMed ID: 33084183
[TBL] [Abstract][Full Text] [Related]
5. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
6. Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.
Zhang W; Liu B; Wu W; Li L; Broom BM; Basourakos SP; Korentzelos D; Luan Y; Wang J; Yang G; Park S; Azad AK; Cao X; Kim J; Corn PG; Logothetis CJ; Aparicio AM; Chinnaiyan AM; Navone N; Troncoso P; Thompson TC
Clin Cancer Res; 2018 Feb; 24(3):696-707. PubMed ID: 29138344
[No Abstract] [Full Text] [Related]
7. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
8. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
9. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
Basourakos SP; Li L; Aparicio AM; Corn PG; Kim J; Thompson TC
Curr Med Chem; 2017; 24(15):1586-1606. PubMed ID: 27978798
[TBL] [Abstract][Full Text] [Related]
10. Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.
Palmbos PL; Hussain MH
Oncology (Williston Park); 2016 May; 30(5):377-85. PubMed ID: 27188668
[TBL] [Abstract][Full Text] [Related]
11. Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics.
Gong J; Posadas E; Bhowmick N; Kim H; Daskivich T; Gupta A; Sandler H; Kamrava M; Zumsteg Z; Freedland S; Figlin R
Oncology (Williston Park); 2021 Mar; 35(3):119-125. PubMed ID: 33818052
[TBL] [Abstract][Full Text] [Related]
12. The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment.
Li S; Wang L; Wang Y; Zhang C; Hong Z; Han Z
J Hematol Oncol; 2022 Oct; 15(1):147. PubMed ID: 36253861
[TBL] [Abstract][Full Text] [Related]
13. Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic.
Ghose A; Moschetta M; Pappas-Gogos G; Sheriff M; Boussios S
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575947
[TBL] [Abstract][Full Text] [Related]
14. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action.
Pommier Y; O'Connor MJ; de Bono J
Sci Transl Med; 2016 Oct; 8(362):362ps17. PubMed ID: 27797957
[TBL] [Abstract][Full Text] [Related]
15. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
Brown JS; O'Carrigan B; Jackson SP; Yap TA
Cancer Discov; 2017 Jan; 7(1):20-37. PubMed ID: 28003236
[TBL] [Abstract][Full Text] [Related]
16. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
[TBL] [Abstract][Full Text] [Related]
17. Approaches for Identifying Novel Targets in Precision Medicine: Lessons from DNA Repair.
Williams DT; Staples CJ
Adv Exp Med Biol; 2017; 1007():1-16. PubMed ID: 28840549
[TBL] [Abstract][Full Text] [Related]
18. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
19. PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy.
Kruse V; Rottey S; De Backer O; Van Belle S; Cocquyt V; Denys H
Acta Clin Belg; 2011; 66(1):2-9. PubMed ID: 21485757
[TBL] [Abstract][Full Text] [Related]
20. Targeting DNA damage response pathways in cancer.
Groelly FJ; Fawkes M; Dagg RA; Blackford AN; Tarsounas M
Nat Rev Cancer; 2023 Feb; 23(2):78-94. PubMed ID: 36471053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]